News | February 09, 2010

U.S. Insurers to Cover Radioembolization for Liver Cancer

February 9, 2010 - About 22,600 cases of primary liver cancer are diagnosed each year in the U.S. and one million annually worldwide, reports the American Cancer Society.

Two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, marking the largest favorable determinations for reimbursement coverage for this treatment by U.S. insurers.

The most common form of primary liver cancer is hepatocellular carcinoma (HCC), which in the U.S. is commonly caused by alcohol abuse or by the hepatitis B or hepatitis C virus. HCC is the fifth most common form of cancer in the world and is increasing globally due to an increase in the incidence of hepatitis. Treatment options for patients with primary liver cancer are limited as HCC is usually unresectable.

An important technique for treating radioembolization, also called selective internal radiation therapy (SIRT), is a process by which small beads or microspheres, containing the radioactive element yttrium-90, are delivered directly to the tumor using the tumor's own blood supply.

One form of radioembolization, TheraSphere by MDS Nordion, will now be reimbursed. TheraSphere is a low toxicity, liver cancer therapy that consists of millions of micro-glass beads containing radioactive yttrium-90. The product is injected by physicians into the main artery of the patient's liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood vessels. The TheraSphere treatment can generally be administered on an outpatient basis and does not usually require an overnight hospital stay. After treatment, most TheraSphere patients are eligible for further therapeutic options because the procedure preserves liver vascularity.

For more information: www.mdsnordion.com/therasphere

Related Content

What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...
360_NW_Proton_Center_Gantry_Room_Back_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 photo view behind the gantry room at the ...
360_NW_Proton_Center_Inclined_Room_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 view of Treatment Room 3 (of 4) at the N...
NW Proton Center Gantry Room Front
360 Photos | 360 View Photos | February 27, 2019
This is a 360 photo view inside the gantry room at the...
Videos | Proton Therapy | February 26, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...
Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.